<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[7, 10] acute adverse events<br>[45, 51] acute adverse events (AEs)<br>[145, 147] Adverse events<br>[235, 237] AEs.<br>[280, 287] Diarrhea was the most common AE,<br>[348, 350] severe diarrhea<br>[398, 400] severe diarrhea<br>[436, 439] severe diarrhea.<br>[454, 456] acute AEs<br></td>
<td width=33%>
[7, 10] acute adverse events<br>[45, 51] acute adverse events (AEs)<br>[145, 147] Adverse events<br>[235, 237] AEs.<br>[280, 287] Diarrhea was the most common AE,<br>[348, 350] severe diarrhea<br>[398, 400] severe diarrhea<br>[436, 439] severe diarrhea.<br>[454, 456] acute AEs<br></td>
<td width=33%>
[7, 10] acute adverse events<br>[36, 42] nucleotide polymorphism (SNP) of<br>[44, 51] and acute adverse events (AEs)<br>[145, 166] Adverse events were graded according to the Common Terminology Criteria for Adverse Events, v. 3.0 (CTCAE v3.0).<br>[199, 201] acute AEs<br>[234, 237] severe AEs.<br>[240, 250] frequencies of the three genotypes GG, GA and AA<br>[276, 280] without severe AEs.<br>[280, 290] Diarrhea was the most common AE, and severe diarrhea<br>[296, 306] frequencies of the three genotypes GG, GA and AA<br>[334, 338] without severe diarrhea.<br>[346, 356] risk for severe diarrhea in patients with AA genotype (<br>[370, 375] GG or GA genotypes.<br>[395, 400] increased risk for severe diarrhea<br>[434, 440] risk of severe diarrhea.
<br>[450, 464] potential biomarker for predicting acute AEs in postoperative stage II and III rectal cancer<br></td>
</tr>
